Summary
The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target of the drug is relevant to pediatric oncology. This is expected to drive a substantial increase in the number of trials seeking to enroll children. Parents and caregivers are likely to have many questions when considering whether to enroll a child in a clinical trial, and children, perhaps particularly adolescents, will also have their own lists of questions, so adequate time must be allowed for these questions to be asked and answered.
Register to download
Parents as Gatekeepers for Children with Cancer
You may also be interested in:
White Paper
RACE Act Prompts More Pediatric Clinical Trials for Oncology Drug Developers
The Food and Drug Administration (FDA) is enacting the Research to Accelerate Cures & Equity (RACE) for Children Act amends and updates the Pediatric…
Blog
Ask the Experts: How Can We Ensure Pediatric Oncology is at the Forefront of Legislation?
LeAnn joined PRA in October 2018 as a Senior Project Manager, working primarily on oncology clinical trials. We sat down with her to hear her…
Blog
The RACE Act: Your next steps start here.
The Research to Accelerate Cures and Equity (RACE) for Children Act went into effect on August 18, 2020 and impacts pediatric cancer drug development.